|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: EIF3B |
Gene summary for EIF3B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | EIF3B | Gene ID | 8662 |
| Gene name | eukaryotic translation initiation factor 3 subunit B | |
| Gene Alias | EIF3-ETA | |
| Cytomap | 7p22.3 | |
| Gene Type | protein-coding | GO ID | GO:0001732 | UniProtAcc | A0A024R821 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8662 | EIF3B | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.10e-04 | 5.49e-01 | -0.0811 |
| 8662 | EIF3B | HTA11_78_2000001011 | Human | Colorectum | AD | 5.91e-07 | 5.41e-01 | -0.1088 |
| 8662 | EIF3B | HTA11_347_2000001011 | Human | Colorectum | AD | 5.60e-09 | 4.74e-01 | -0.1954 |
| 8662 | EIF3B | HTA11_83_2000001011 | Human | Colorectum | SER | 1.31e-03 | 5.16e-01 | -0.1526 |
| 8662 | EIF3B | HTA11_696_2000001011 | Human | Colorectum | AD | 1.79e-06 | 4.67e-01 | -0.1464 |
| 8662 | EIF3B | HTA11_866_2000001011 | Human | Colorectum | AD | 1.58e-02 | 2.75e-01 | -0.1001 |
| 8662 | EIF3B | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.66e-12 | 8.17e-01 | -0.059 |
| 8662 | EIF3B | HTA11_866_3004761011 | Human | Colorectum | AD | 5.12e-18 | 7.51e-01 | 0.096 |
| 8662 | EIF3B | HTA11_8622_2000001021 | Human | Colorectum | SER | 9.59e-04 | 5.76e-01 | 0.0528 |
| 8662 | EIF3B | HTA11_10623_2000001011 | Human | Colorectum | AD | 3.92e-05 | 7.16e-01 | -0.0177 |
| 8662 | EIF3B | HTA11_7696_3000711011 | Human | Colorectum | AD | 6.01e-17 | 7.09e-01 | 0.0674 |
| 8662 | EIF3B | HTA11_6818_2000001021 | Human | Colorectum | AD | 4.62e-08 | 5.61e-01 | 0.0588 |
| 8662 | EIF3B | HTA11_99999970781_79442 | Human | Colorectum | MSS | 2.66e-26 | 8.44e-01 | 0.294 |
| 8662 | EIF3B | HTA11_99999965104_69814 | Human | Colorectum | MSS | 2.11e-27 | 1.24e+00 | 0.281 |
| 8662 | EIF3B | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.14e-32 | 1.28e+00 | 0.3859 |
| 8662 | EIF3B | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.35e-09 | 8.98e-01 | 0.2585 |
| 8662 | EIF3B | HTA11_99999974143_84620 | Human | Colorectum | MSS | 2.93e-20 | 8.35e-01 | 0.3005 |
| 8662 | EIF3B | A015-C-203 | Human | Colorectum | FAP | 3.24e-08 | -5.01e-02 | -0.1294 |
| 8662 | EIF3B | A002-C-201 | Human | Colorectum | FAP | 2.29e-05 | -5.78e-02 | 0.0324 |
| 8662 | EIF3B | A001-C-119 | Human | Colorectum | FAP | 8.27e-04 | -2.43e-01 | -0.1557 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0022613111 | Esophagus | ESCC | ribonucleoprotein complex biogenesis | 365/8552 | 463/18723 | 1.74e-49 | 1.11e-45 | 365 |
| GO:0002181111 | Esophagus | ESCC | cytoplasmic translation | 135/8552 | 148/18723 | 4.17e-32 | 2.65e-29 | 135 |
| GO:0016032111 | Esophagus | ESCC | viral process | 301/8552 | 415/18723 | 3.34e-29 | 1.32e-26 | 301 |
| GO:0006413110 | Esophagus | ESCC | translational initiation | 100/8552 | 118/18723 | 1.16e-18 | 1.25e-16 | 100 |
| GO:0006417111 | Esophagus | ESCC | regulation of translation | 304/8552 | 468/18723 | 1.53e-17 | 1.33e-15 | 304 |
| GO:0071826111 | Esophagus | ESCC | ribonucleoprotein complex subunit organization | 166/8552 | 227/18723 | 2.94e-17 | 2.42e-15 | 166 |
| GO:0022618111 | Esophagus | ESCC | ribonucleoprotein complex assembly | 159/8552 | 220/18723 | 8.19e-16 | 5.71e-14 | 159 |
| GO:001908017 | Esophagus | ESCC | viral gene expression | 80/8552 | 94/18723 | 2.04e-15 | 1.28e-13 | 80 |
| GO:000644617 | Esophagus | ESCC | regulation of translational initiation | 65/8552 | 79/18723 | 2.04e-11 | 7.07e-10 | 65 |
| GO:0002183110 | Esophagus | ESCC | cytoplasmic translational initiation | 32/8552 | 34/18723 | 2.18e-09 | 4.94e-08 | 32 |
| GO:001908116 | Esophagus | ESCC | viral translation | 16/8552 | 16/18723 | 3.56e-06 | 3.92e-05 | 16 |
| GO:0001732110 | Esophagus | ESCC | formation of cytoplasmic translation initiation complex | 15/8552 | 16/18723 | 7.15e-05 | 5.38e-04 | 15 |
| GO:007552210 | Esophagus | ESCC | IRES-dependent viral translational initiation | 11/8552 | 11/18723 | 1.80e-04 | 1.16e-03 | 11 |
| GO:002261322 | Liver | HCC | ribonucleoprotein complex biogenesis | 355/7958 | 463/18723 | 7.76e-52 | 4.92e-48 | 355 |
| GO:000218122 | Liver | HCC | cytoplasmic translation | 132/7958 | 148/18723 | 9.09e-33 | 5.76e-30 | 132 |
| GO:001603222 | Liver | HCC | viral process | 286/7958 | 415/18723 | 4.41e-28 | 1.86e-25 | 286 |
| GO:007182622 | Liver | HCC | ribonucleoprotein complex subunit organization | 159/7958 | 227/18723 | 3.14e-17 | 3.06e-15 | 159 |
| GO:000641722 | Liver | HCC | regulation of translation | 287/7958 | 468/18723 | 8.79e-17 | 8.08e-15 | 287 |
| GO:000641322 | Liver | HCC | translational initiation | 94/7958 | 118/18723 | 1.39e-16 | 1.24e-14 | 94 |
| GO:002261822 | Liver | HCC | ribonucleoprotein complex assembly | 153/7958 | 220/18723 | 3.44e-16 | 2.91e-14 | 153 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| EIF3B | SNV | Missense_Mutation | c.1311C>A | p.Phe437Leu | p.F437L | P55884 | protein_coding | tolerated(0.06) | benign(0.184) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| EIF3B | SNV | Missense_Mutation | novel | c.2194N>C | p.Glu732Gln | p.E732Q | P55884 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| EIF3B | SNV | Missense_Mutation | c.2264A>G | p.Glu755Gly | p.E755G | P55884 | protein_coding | deleterious(0) | benign(0.218) | TCGA-E2-A15D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| EIF3B | insertion | Nonsense_Mutation | novel | c.781_782insCTAGAATTATCAAATACAGGTAATGCTGC | p.Phe261SerfsTer8 | p.F261Sfs*8 | P55884 | protein_coding | TCGA-A2-A04V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | PD | ||
| EIF3B | insertion | Frame_Shift_Ins | novel | c.1598_1599insGCTAATAAGCTTTTTACTGAGA | p.Pro534LeufsTer19 | p.P534Lfs*19 | P55884 | protein_coding | TCGA-A2-A04V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | PD | ||
| EIF3B | insertion | Frame_Shift_Ins | novel | c.1995_1996insTCCAGGACTCAGGCCAAGCCCGCACAGA | p.Val666SerfsTer20 | p.V666Sfs*20 | P55884 | protein_coding | TCGA-A8-A093-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| EIF3B | insertion | Frame_Shift_Ins | novel | c.1802_1803insCCGCCCTTCCAGGCAGGGAG | p.Glu601AspfsTer35 | p.E601Dfs*35 | P55884 | protein_coding | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD | |||
| EIF3B | SNV | Missense_Mutation | rs759606657 | c.1907C>T | p.Ala636Val | p.A636V | P55884 | protein_coding | tolerated(0.4) | benign(0.014) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| EIF3B | SNV | Missense_Mutation | rs370274071 | c.1996G>A | p.Val666Ile | p.V666I | P55884 | protein_coding | tolerated(0.07) | benign(0.342) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| EIF3B | SNV | Missense_Mutation | c.1311C>G | p.Phe437Leu | p.F437L | P55884 | protein_coding | tolerated(0.06) | benign(0.184) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |